XTL Biopharmaceuticals (XTLB) Slashes 75% of Workforce
More News related to XTLB
- XTL Biopharmaceuticals (XTLB) Slashes 75% of Workforce
- Unusual 11 Mid-Day Movers 11/18: IDMI, PSUN, DHT, CQB Higher; XTLB, NCOC, SKS, DIVX Lower
- Ladenburg Thalmann Downgrades XTL Biopharmaceuticals (XTLB) to Sell
- Pre-Open Movers: Winnebago (WGO) Sinks On Poor Results, Borders (BGP) Up On Earnings/Strategic Review
- XTL Biopharmaceuticals (XTLB) Announces Licensing of its Pre-Clinical Program in Hepatitis C to Presidio
More News related to Corporate News
- Highlights From DE's Q4 Conference Call: Production Will Pick Up in 2010, But Overall Conditions to Remain Fairly Restrained
- pSivida (PSDV) Files $41.99M Mixed Securities Shelf
- HF Financial (HFFC) Closes $23M Common Offering
- Basic Energy Services (BAS) Closes $225M Senior Note Exchange Offer
- Microsoft (MSFT) and eBay (EBAY) Team Up to Offer Deals Through IE8 Web Slice
XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB) is restructuring its operations following the failure of the Bicifadine Phase 2b clinical trial. The company is terminating the employment of 9 employees, representing 75% of its workforce. The remaining employees will be responsible for seeking potential assets or a company to merge into XTL, or for assisting in the liquidation and/or disposition of XTL's assets.
XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of diabetic neuropathic pain and hepatitis C. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
